Risk-reducing salpingo-oophorectomy among Chinese women at increased risk of breast and ovarian cancer

[1] Berek JS(2018)Cancer of the ovary, fallopian tube, and peritoneum Int J Gynaecol Obstet 143 59-78

[2] Kehoe ST(2005)BRCA1 and BRCA2 as ovarian cancer susceptibility genes Carcinogenesis 26 1651-6

[3] Kumar L(2016)Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome, and beyond Gynecol Oncol 140 565-74

[4] Friedlander M(2014)Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas Clin Cancer Res 20 764-75

[5] Sowter HM(2021)Genetic/Familial High-Risk Assessment: breast, ovarian, and pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology J Natl Compr Canc Netw 19 77-102

[6] Ashworth A(2020)Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: a systematic review and meta-analysis Eur J Surg Oncol 46 139-47

[7] Hall MJ(2017)Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers J Gynecol Oncol 28 e3-20

[8] Obeid EI(2020)Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: a large prospective single institution experience Gynecol Oncol 157 514-83

[9] Schwartz SC(2014)Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199 J Clin Oncol 32 3275-32

[10] Mantia-Smaldone G(2005)Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy J Clin Oncol 23 127-9

[1] Berek JS(2018)Cancer of the ovary, fallopian tube, and peritoneum Int J Gynaecol Obstet 143 59-78

[2] Kehoe ST(2005)BRCA1 and BRCA2 as ovarian cancer susceptibility genes Carcinogenesis 26 1651-6

[3] Kumar L(2016)Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome, and beyond Gynecol Oncol 140 565-74

[4] Friedlander M(2014)Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas Clin Cancer Res 20 764-75

[5] Sowter HM(2021)Genetic/Familial High-Risk Assessment: breast, ovarian, and pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology J Natl Compr Canc Netw 19 77-102

[6] Ashworth A(2020)Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: a systematic review and meta-analysis Eur J Surg Oncol 46 139-47

[7] Hall MJ(2017)Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers J Gynecol Oncol 28 e3-20

[8] Obeid EI(2020)Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: a large prospective single institution experience Gynecol Oncol 157 514-83

[9] Schwartz SC(2014)Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199 J Clin Oncol 32 3275-32

[10] Mantia-Smaldone G(2005)Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy J Clin Oncol 23 127-9